Category: Knowledge Base

Disclaimer: Compounded tirzepatide is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. This article reflects my perspective as a founder and our program’s practice observations. It is not medical advice and does not establish a provider-patient relationship.

“How long until it works?” is the question almost every patient asks before starting tirzepatide, and the honest answer has two parts, because tirzepatide works on two different timelines. It changes your appetite fairly quickly, and it changes your weight gradually. Confusing those two is where most early frustration comes from. Let me give you a realistic timeline based on what our program actually sees.

The First Thing You Notice: Appetite, Often Within the First Week

The earliest change most patients report is not a number on the scale. It is a shift in appetite and their whole relationship with food.

Many people notice it within the first week or so: the constant background hunger quiets down, cravings ease, and what some patients call “food noise,” the persistent mental chatter about eating, gets noticeably softer. Portions that used to feel normal start to feel like too much. This is the appetite effect taking hold, and it is what patients feel first, before the scale reflects anything.

I want to set an honest expectation, though: at the starting dose, this effect is usually gentle rather than dramatic. Tirzepatide is deliberately started low and increased gradually over weeks to minimize side effects, so the first weeks are often a subtle shift, not a dramatic switch. That gradual ramp is intentional and it is a good thing.

The Scale: Measurable Change Over Weeks to Months

Weight loss follows the appetite change, and it follows gradually. This is where expectations most need grounding.

In our program, patients generally begin to see measurable movement on the scale within the first several weeks, but the meaningful, sustained loss builds over months, as the dose steps up toward its target and the reduced appetite translates into a consistent calorie deficit maintained over time. This is not an overnight process, and the patients who do best are the ones who expect a marathon rather than a sprint.

The steady pace is a feature. Gradual, consistent loss is more sustainable and easier on the body than rapid drops, and it gives the eating habits around the medication time to actually change.

Why the Dose Schedule Shapes Your Timeline

Tirzepatide is not started at its full dose. It is titrated: a low starting dose increased in steps over weeks under your provider’s guidance. This directly shapes what you experience early on, because your first weeks are on a fraction of the eventual dose.

That means the first month is partly an adjustment and ramp-up period. The fuller effect arrives as you progress up the dose schedule. Patients who expect the starting dose to deliver everything are often puzzled that the early weeks feel modest, and the explanation is simply that you have not reached your working dose yet.

What Affects Your Personal Timeline

Individual response varies, and for understandable reasons. Starting weight, metabolism, diet, activity level, sleep, and consistency all influence how quickly results show. The single biggest factor you control is what you do around the medication: patients who pair tirzepatide with adequate protein, some resistance training, and reasonable consistency get better and more durable results than those relying on the medication alone.

I will be direct, because it matters: tirzepatide is a genuinely powerful tool, but it is not a substitute for the fundamentals. What it does is make the fundamentals dramatically easier to sustain by quieting appetite. The patients who treat that as permission to ignore diet and movement leave much of the benefit unrealized. For more on protecting your results, see our article on preventing muscle loss on GLP-1 therapy.

A Realistic Summary

Here it is in plain terms. Appetite and food-noise changes: often within the first week, usually gentle at first. Early measurable weight change: within the first several weeks. Meaningful, sustained loss: over months, as the dose reaches target and consistency compounds. If you expect a dramatic scale drop in week one, you will be frustrated. If you understand that appetite quiets first and weight follows steadily, the process makes sense and it works.

To learn more about our program and how compounded tirzepatide is offered, visit our compounded tirzepatide online page.

This article reflects my personal perspective as a founder and our program’s practice observations. It is not medical advice and does not establish a provider-patient relationship. Individual results vary. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult a licensed provider.

JP Rius is the founder of Precision Telemed. Over the past two years his clinical team has served more than 5,000 patients across weight loss, hormone therapy, peptide therapy, and longevity programs.

Disclaimer: Compounded tirzepatide and sermorelin are prepared by a licensed 503A compounding pharmacy and have not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

About eight months into running our weight loss program, I started noticing a pattern I did not like. Patients on tirzepatide were losing weight — exactly as the data predicted. But a subset were describing something that went beyond fat loss. They were losing strength. Recovery was slower. They said they felt lighter but not better.

That pattern is what led me to build the tirzepatide and sermorelin combination program. From a pharmaceutical standpoint, I could see what was happening and why. I was not going to keep watching it.

What the Science Says About Lean Mass Loss on GLP-1 Therapy

This is the part most weight loss programs skip, and I think it is the most important conversation to have before someone starts. I am not going to frame it as clinical guidance, but I can explain the pharmacology clearly.

When the body enters a sustained caloric deficit, it draws energy from stored sources. Fat is the primary target, but the body also converts muscle-derived amino acids to glucose through gluconeogenesis. When growth hormone is already declining with age and the anabolic environment is already compromised, the body has less capacity to preferentially burn fat and spare protein. More of what comes off is lean mass.

Our clinical team sees this pattern consistently: a meaningful share of the weight lost on GLP-1 therapy is lean tissue rather than fat, particularly in patients not engaged in structured resistance training. This is a GLP-1 class pattern, not a specific drug problem, and it is exactly what the sermorelin pairing is designed to address.

For the full protocol on protecting lean mass — protein targets, training requirements, the leucine threshold, our clinical team explains this in detail and our doctor blog covers it at The Protein and Resistance Training Protocol for GLP-1 Patients.

Why the Sermorelin Stack Makes Pharmacological Sense

Sermorelin works through the GHRH receptor on pituitary somatotrophs, stimulating GH release in the natural pulsatile pattern. GH then drives IGF-1 production in the liver, and IGF-1 activates the PI3K/Akt/mTOR pathway at muscle cells — the primary intracellular signal for muscle protein synthesis. During a caloric deficit, mTOR is suppressed by low nutrient availability and reduced insulin signaling. Sermorelin-driven IGF-1 elevation provides a compensatory anabolic signal that partially offsets that suppression.

The two mechanisms are orthogonal. Tirzepatide handles the energy intake and fat metabolism side through the GLP-1 and GIP pathways. Sermorelin handles tissue preservation through the GHRH/GH/IGF-1 axis. They don’t overlap; they complement each other.

For more on what sermorelin does and the realistic timeline, see What Patients Actually Report After 90 Days on Sermorelin. For the full tirzepatide mechanism and how it compares to semaglutide, see Tirzepatide vs Semaglutide: What the Data Shows.

What I Observe in Our Patient Population

Patients on the combination program consistently describe a different qualitative experience at the end of the weight loss phase than patients on tirzepatide alone. They feel stronger. They look leaner rather than just smaller. One patient three months into the stack described it as the difference between losing weight and actually changing his body. He had done a GLP-1-only protocol two years earlier and arrived at his target weight feeling depleted. On the combination, he arrived at the same weight feeling strong and recovered.

That matches what the mechanism predicts. It is what I observe consistently enough to have made the combination a formal offering rather than a case-by-case decision.

Why Lean Mass Protection Matters Beyond the Scale

Muscle is metabolically active tissue. It burns calories at rest and supports the resting metabolic rate that determines how sustainable weight maintenance will be. Patients who lose significant lean mass during a weight loss phase often arrive at a lower number on the scale with a slower metabolism and feel physically worse than expected. Building the combination program was my way of taking a longer view on the outcome.

A Note on the Regulatory Environment

Both compounded tirzepatide online and compounded sermorelin are prepared at our 503A pharmacy and have not been reviewed or approved by the FDA. The shortage-based pathway that permitted broad tirzepatide compounding ended in late 2024. The current operative framework is 503A patient-specific compounding with documented clinical justification at the prescription level. Our clinical team handles that documentation for every patient.

What the Program Costs

The first month of the tirzepatide and sermorelin stack is $349.99. Both medications are compounded at our 503A pharmacy and the program runs under physician oversight through our telehealth platform. Compared to medical weight loss clinics where tirzepatide alone is often $400–600 a month with separate fees for additional prescriptions, $349.99 for the full stack is materially more accessible.

The pricing is secondary to the clinical rationale. The question worth asking before any weight loss program is not just how much weight will be lost — it is what the body will look like and how it will function when the process is complete.

FAQ

Can tirzepatide and sermorelin be taken together? Our clinical team uses this combination intentionally. Tirzepatide works through GLP-1 and GIP receptor pathways. Sermorelin works through the GHRH receptor on the pituitary, driving GH and IGF-1 production through a completely separate mechanism. The two don’t conflict. Both are compounded medications that have not been reviewed by the FDA.

Does sermorelin help with weight loss? Sermorelin is not a primary weight loss therapy. It supports body composition by helping preserve lean muscle mass during a caloric deficit through GH-driven protein sparing and IGF-1 mediated anabolic signaling. Our clinical team evaluates each patient’s situation individually.

Why do patients lose muscle during weight loss? During sustained caloric deficit, the body converts muscle-derived amino acids to glucose through gluconeogenesis. mTOR suppression from low nutrient availability also reduces muscle protein synthesis. A meaningful share of weight lost on GLP-1 therapy comes from lean tissue. Sermorelin addresses this through the GH/IGF-1 axis.

How much does the stack cost? $349.99 for the first month at Precision Telemed, including both medications and physician oversight.

If you want to talk through whether this is right for you, our providers are available online. Start at www.precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.

About the Author: JP Rius is the founder of Precision Telemed with a background in pharmaceutical commercial sales, operations, and trade. Over the past two years, his clinical team has served more than 5,000 patients across weight loss, hormone therapy, peptide therapy, and longevity programs. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

A patient messaged me last spring asking about skipping from 2.5mg directly to 7.5mg on tirzepatide because he had read online that the higher doses work better. He was not wrong that higher doses can produce more weight loss. He was wrong about the timeline. The titration schedule is not a formality — it is a clinical tool, and rushing it produces exactly the outcome it is designed to prevent: weeks of nausea that drive patients to quit.

I have been managing patients on tirzepatide for over two years, and dose escalation protocol is one of the most consistently misunderstood parts of this therapy. Understanding why the schedule exists requires understanding how tirzepatide’s biology actually works at the receptor level.

What Tirzepatide Does That Single-Agonist Medications Do Not

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It activates two separate incretin hormone pathways simultaneously through a single molecule. GIP receptors are expressed on pancreatic beta cells and alpha cells, meaning GIP directly participates in insulin and glucagon regulation. They are also expressed in adipose tissue, where GIP has a direct lipolytic effect, stimulating fat breakdown in a way that GLP-1 alone does not. GIP receptors are additionally found in bone and in the central nervous system.

This broader receptor distribution explains why the dual agonist approach produces a qualitatively different physiological effect rather than simply a stronger version of what a GLP-1 agonist does alone. For a full comparison of how tirzepatide and semaglutide differ in mechanism, see Tirzepatide vs Semaglutide.

In our practice, the dose-dependent pattern is consistent: patients tend to see progressively more weight loss as they move up through the dose range, which is exactly why the titration schedule and the target dose matter so much to the outcome.

The Standard Titration Schedule and Its Rationale

The titration schedule I follow begins at 2 mg once weekly. After four weeks at that dose, patients move to 4.25mg. Every four weeks thereafter, the dose increases by 2.5mg, moving through 12.5mg, and up to a maximum of 15mg. The full titration to maximum dose takes approximately 20 weeks.

The clinical rationale for slow escalation is grounded in the pharmacology of GIP and GLP-1 receptor activation on gastrointestinal motility. Tirzepatide’s GLP-1 component slows gastric emptying and alters enteric nervous system signaling, and the gut requires time to adapt to this new baseline. The side effects most pronounced at dose increases — primarily nausea and loose stools — are driven largely by this motility change. When the dose increases too rapidly, the motility shift outpaces the adaptive downregulation of gut sensitivity to the drug.

In my own patients, nausea reliably clusters in the first week or two after each dose increase and eases as the gut adapts. It is very manageable with proper titration and patient education. For more on managing GI side effects, see The Titration Protocol We Changed After Hearing the Same Complaint From Hundreds of Patients.

Rushed escalation is not merely uncomfortable — persistent nausea leads to poor food intake, disrupts protein consumption, and contributes to lean mass loss beyond what the medication’s fat-burning effects would otherwise produce.

What Drives a Dose Increase Versus Holding Steady

The standard protocol calls for dose increases at four-week intervals, but in clinical practice I individualize this decision. If a patient is still experiencing meaningful nausea or gastrointestinal disruption at week three of a new dose, I extend the hold by two to four additional weeks before moving up. The goal is not to reach a target dose on a particular calendar date. The goal is to reach the highest dose the patient tolerates well and sustains without ongoing distress.

Patients often ask whether reaching 15mg is necessary to see results. The answer is no. In my practice, many patients reach their goals at 5mg or 10mg. A patient who tolerates a mid-range dose well and is losing weight consistently does not always need to push higher.

Recognizing Side Effects That Signal Slowing Escalation

The side effects I take most seriously as indicators to pause escalation are persistent nausea that is not improving week over week, vomiting that occurs more than once in a week, and significant reductions in food intake that push caloric levels below what sustains lean mass. Constipation is common and manageable with increased water intake and fiber. Some patients benefit from a daily osmotic laxative during the early titration period.

Persistent low energy or mood changes beyond two weeks of a new dose warrant a follow-up conversation before proceeding with the next escalation step.

Early Slow Response Is Not Failure

One of the most reassuring things I tell patients is that a slow start is not a failed start. In my experience, patients who show only modest change in the first several weeks very often go on to meaningful weight reduction once they have had enough time at the right dose. An early slow response is usually a sign that the patient needs more time at the current dose before advancing, or that the titration schedule needs to be extended to allow fuller receptor adaptation.

Tirzepatide Dosage Chart Reference

The standard weekly dose schedule is as follows:

• Weeks 1–4: 2 or 2.5 mg
• Weeks 5–8: 4.25 or 5 mg
• Weeks 9–12: 7.5 mg
• Weeks 13–16: 10 mg
• Weeks 17–20: 12.5 mg
• Week 21 onward: 14 or 15 mg maintenance dose

Individual schedules are adjusted based on tolerability and clinical response.

A Note on Compounded Tirzepatide

The regulatory framework for compounded tirzepatide has changed since 2024. The FDA declared the tirzepatide shortage resolved in late 2024, which ended the broad shortage-based compounding pathway. What remains available is 503A patient-specific compounding when a licensed prescriber documents a clinical reason the commercial product does not meet the individual patient’s need. Compounded tirzepatide has not been reviewed or approved by the FDA and is not the same as commercially available Mounjaro or Zepbound. Because it is not FDA-reviewed, its potency and purity are not assured in the way an approved product’s are.

At Precision Telemed, patients can access compounded tirzepatide online through a telehealth program available in all 50 states, for patients whose clinical situation is appropriate and documented under the current 503A framework.

FAQ

Q: Is reaching 15mg necessary to lose weight on tirzepatide? No. In our practice, patients achieve meaningful weight loss across the dose range, and many reach their goals well below the maximum. The treating provider determines the appropriate target dose based on individual tolerance and response.

Q: How long does nausea from tirzepatide typically last? Nausea is most common in the first one to two weeks at each new dose level. For most patients, it improves significantly by week two. Taking tirzepatide with a small amount of food and staying well hydrated reduces the severity for most patients.

Q: What happens if a dose is missed? If less than four days have passed since the missed dose, the medication should be taken as soon as possible and the regular weekly schedule resumed. If five or more days have passed, the missed dose should be skipped and the next dose taken on the regularly scheduled day.

Q: Can a patient stay at a lower dose permanently if results are good? Yes. If a patient is achieving good results and tolerating a given dose well, there is no clinical requirement to advance to the maximum. This is a shared decision between the patient and their provider based on individual goals and response.

Q: Is compounded tirzepatide the same medication as the brand-name version? Compounded tirzepatide is formulated by a 503A pharmacy. It has not been reviewed or approved by the FDA and is not the same as Mounjaro or Zepbound. Because it is not FDA-reviewed, its potency, purity, and clinical performance cannot be assumed to match the approved products.

Q: How soon will patients see results? Most patients experience appetite changes within the first two weeks. Measurable weight loss typically becomes apparent by weeks four to six.

To speak with one of our licensed providers about whether this is right for you, visit www.precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.

Disclaimer: Compounded sermorelin is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

Six weeks into his sermorelin protocol, a patient reached out to our team and said he had something to report. He was 51. He had been waking up two or three times a night for as long as he could remember. He had accepted it as something that just happens with age. Six weeks after starting sermorelin, he had slept through the night every night for two weeks. His wife noticed before he did.

That pattern is not unusual. Over two years and hundreds of sermorelin patients in our program, our team has heard some version of it more times than we can count. And the timing, sleep first, before anything else, is not coincidental. It has everything to do with how the molecule works.

What Sermorelin Is: From a Pharmaceutical Standpoint

Sermorelin is a synthetic analog of growth hormone releasing hormone, or GHRH. I want to explain the pharmacology here as someone with a pharmaceutical background, not as clinical guidance.

Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary. Those receptors are G-protein coupled. When GHRH binds, they activate adenylyl cyclase, which raises intracellular cAMP, which triggers GH synthesis and release in a pulsatile pattern. The key word is pulsatile. GH releases in bursts, primarily during deep slow-wave sleep, and the amplitude of those pulses is what determines overall GH activity across a 24-hour period.

Sermorelin amplifies that natural pulsatile release rather than introducing exogenous hormone. Somatostatin, the hypothalamic brake on GH secretion, still applies. The pituitary can still modulate the response. That’s a pharmacologically meaningful distinction from direct HGH therapy, which bypasses the feedback loop entirely.

Research by Corpas and colleagues documented that GH secretion decreases by approximately 14 percent per decade after age 30 (Corpas et al., Endocr Rev 1993, PMID 8491152). By the mid-40s or 50s, GH output may be a fraction of what it was in someone’s 20s. GH’s primary downstream mediator is IGF-1, produced in the liver in response to GH signaling. When GH declines, IGF-1 falls with it, and the anabolic signaling across muscle, bone, and connective tissue weakens.

Sleep Comes First: And Here’s Why

The majority of daily GH secretion happens during slow-wave sleep. When sermorelin begins restoring the amplitude of that nocturnal pulse, what our patients experience first is a qualitative change in sleep. Across hundreds of patients in our program, the pattern is consistent: sleep changes in weeks two to four, before anything visible happens.

That 51-year-old patient’s two weeks of uninterrupted sleep weren’t coincidental. They were what restored somatotroph function looks like in practice.

The relationship between GHRH administration and sleep architecture is documented. Steiger and colleagues showed pulsatile GHRH administration increased slow-wave sleep from 14.0 to 20.2 percent of total sleep time, a 44 percent relative increase, alongside elevated nocturnal GH secretion. That’s the mechanism behind why sleep is the earliest observable signal.

What Comes After: Energy, Recovery, Body Composition

After sleep improves, patients typically describe a baseline shift in energy, not a stimulant effect, but a quieter change where afternoon fatigue arrives later or not at all, and physical recovery tracks more like it used to. The IGF-1 component is relevant here: rising IGF-1 levels support cellular repair and protein synthesis, which determines how quickly someone bounces back from training or physical effort.

Body composition changes take longer. I want to be direct about this because patients often expect them first: visible body composition changes on sermorelin take three to six months. The Rudman 1990 NEJM study, conducted with direct HGH in men over 60, documented measurable lean mass increase and adipose tissue reduction over a six-month window (Rudman et al., NEJM 1990, PMID 2355952). Sermorelin works through the natural pituitary mechanism and won’t produce identical magnitude results, but it operates on the same fundamental axis.

What patients in our program typically report over three to six months: lean muscle holding on better, modest visceral fat reduction, clothes fitting differently, recovery from training improving noticeably. Not dramatic transformation. A meaningful shift that accumulates over time.

What Sermorelin Will Not Do

Sermorelin is not a body recomposition drug. It is not a direct weight loss agent. It will not produce dramatic transformation in isolation. The patients who get the most from it are those who come in with realistic expectations, stay on it long enough for the slower benefits to develop, and treat it as one component of a broader approach to how they take care of themselves.

For the relationship between sermorelin and the testosterone axis, which shares the same nocturnal hormonal window, see Does Sermorelin Increase Testosterone?.

For the clinical dosing detail behind these results, see Sermorelin Dosage for Muscle Growth: A Clinical Guide.

FAQ

When do sermorelin results start showing? Based on what our patient population consistently reports: sleep improvements typically appear in weeks two to four. Energy and recovery improvements follow over the next four to six weeks. Body composition changes develop over three to six months as IGF-1 levels stabilize at a higher baseline. These are observational patterns from our program. Individual results vary, and our clinical team evaluates each patient’s response.

What do patients report before and after sermorelin? Common reports include better sleep quality, faster recovery from exercise, more sustained energy, and gradual body composition improvements over several months. Some patients also report improved hair texture and thickness. Compounded sermorelin has not been reviewed by the FDA.

Is sermorelin the same as HGH? No. Sermorelin works upstream through the GHRH receptor on the pituitary, preserving the body’s natural feedback loop. HGH therapy introduces synthetic growth hormone directly, bypassing that feedback. Different mechanism, different regulatory category, different risk profile.

Does sermorelin help with weight loss? Sermorelin is not a primary weight loss therapy. It can support gradual body composition improvements through the IGF-1 axis. Patients seeking direct weight loss are better served by our dedicated weight loss programs.

What is a realistic sermorelin before and after expectation? Improved sleep, better daily energy, faster recovery, and modest body composition improvements over three to six months. Patients expecting dramatic physical transformation will be disappointed. Patients who want to feel more like a rested, recovered version of themselves consistently report positive outcomes.

References

1. Corpas E et al. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39. PubMed
2. Rudman D et al. Effects of Human Growth Hormone in Men over 60 Years Old. N Engl J Med. 1990;323(1):1-6. PubMed

If you want to talk through whether this is right for you, our providers are available online. Start at www.precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.

About the Author: JP Rius is the founder of Precision Telemed with a background in pharmaceutical commercial sales, operations, and trade. Over the past two years, his clinical team has served more than 5,000 patients across weight loss, hormone therapy, peptide therapy, and longevity programs. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

A patient came to me about eight months ago, a man in his early fifties who had been lifting weights consistently for three decades. He was eating clean, sleeping reasonably well, and his testosterone was within normal range. But he could not hold onto lean mass the way he once had, and he told me recovery after training felt the way it used to feel after overtraining. His IGF-1 came back at 87 ng/mL. That number told most of the story.

When thinking about sermorelin dosage for muscle growth and recovery, it starts here, not with a protocol number, but with understanding what that IGF-1 value represents and why restoring it matters.

What Sermorelin Actually Is and Why It Works Differently From Synthetic HGH

Sermorelin is a 29-amino acid synthetic analogue of growth hormone-releasing hormone, or GHRH. This is the peptide the hypothalamus naturally produces to signal the pituitary to release growth hormone. It does not introduce exogenous growth hormone. It works upstream, stimulating the pituitary to produce and release GH in the pattern it was designed to follow.

The mechanism begins at the somatotroph cells of the anterior pituitary, which express GHRH receptors. These receptors are Gs protein-coupled receptors, meaning when GHRH binds, they activate adenylyl cyclase, which raises intracellular cyclic AMP. The cAMP then activates protein kinase A, which phosphorylates transcription factors that drive GH gene expression. This is not a blunt hormonal override. It is a physiologically embedded signaling pathway that the body already knows how to calibrate.

The pituitary can still modulate the response. Somatostatin counter-regulation, the hypothalamus’s natural brake on GH secretion, still applies. Somatostatin inhibits GH release when GH levels are sufficient, ensuring that sermorelin cannot drive GH into pharmacological excess the way exogenous HGH can. This is the critical practical distinction from synthetic HGH, which delivers GH whether the body needs it or not, at levels that can suppress the natural axis over time.

The Standard Dosing Range and Why Timing Matters

In clinical practice, I dose sermorelin between 200 and 500 micrograms subcutaneously, administered at bedtime. The lower end of that range, 200 to 300 mcg, is appropriate for most patients starting out. I titrate upward based on IGF-1 response at six to eight weeks. Patients who reach the 400 to 500 mcg range and show strong IGF-1 response are generally the ones I keep at a higher dose.

Bedtime dosing is not arbitrary. During waking hours, somatostatin tone is relatively higher, suppressing GH secretion. As the body transitions into slow-wave sleep, somatostatin release falls and GHRH signaling becomes dominant, producing the large nocturnal GH pulse. Administering sermorelin just before this window amplifies a pulse that was already biologically primed to occur.

A 1992 study published in Neuroendocrinology by Steiger and colleagues demonstrated this precisely. Pulsatile GHRH administration increased slow-wave sleep from 14.0 to 20.2 percent of total sleep time, a 44 percent relative increase, alongside elevated nocturnal GH secretion. (PubMed) The fact that GHRH administration increases slow-wave sleep is part of why sermorelin’s benefits extend well beyond what a simple “growth hormone booster” framing would suggest.

I use a five nights on, two nights off protocol with most patients. Continuous daily stimulation over long periods can reduce pituitary responsiveness to GHRH signaling, and the brief rest helps preserve receptor sensitivity by working with the somatostatin system rather than against it.

What to Expect in Weeks 1 Through 4

The first changes patients notice are in sleep quality, not in the mirror. Improved sleep, specifically deeper and less fragmented sleep, is the earliest and most consistent feedback I receive from patients in the first two to four weeks. Some report waking up feeling more rested than they have in years.

The Steiger data helps explain this. The 44 percent relative increase in slow-wave sleep fraction is a large shift in architecture. Patients who have been running on fragmented sleep for years are essentially getting a physiological reset in sleep staging. The downstream effects show up as improved mood, reduced afternoon energy crashes, and faster recovery from exercise. These are the early consequences of improved nocturnal GH activity acting through the very mechanism that slow-wave sleep was designed to support.

Body composition changes in week three are not the signal to watch for. That is not how this works.

Months 2 Through 3: Energy and Early Body Composition Changes

By the second month, IGF-1 levels should be rising meaningfully in patients who are responding well. I check IGF-1 at baseline and again at six to eight weeks. The IGF-1 elevation matters because IGF-1 is the primary effector molecule for GH’s anabolic actions. After GH stimulates the liver to produce IGF-1, that IGF-1 travels through the bloodstream bound primarily to IGF-binding protein 3, or IGFBP-3. The IGFBP-3 carrier protein extends IGF-1’s half-life and serves as a reservoir, releasing IGF-1 at target tissues over time.

At the muscle cell, IGF-1 binds its receptor on the surface of myocytes and activates the PI3K/Akt/mTOR pathway, the central intracellular signaling cascade for muscle protein synthesis. This is the molecular basis for the lean mass accretion that sermorelin supports.

A clinical review by Sigalos and Pastuszak published in Sexual Medicine Reviews found that men treated with growth hormone secretagogue therapy saw IGF-1 levels rise from a mean of 159.5 ng/mL to 239.0 ng/mL over a mean of 134 days, a 50 percent increase with statistical significance. (PubMed) Sermorelin monotherapy at standard doses produces more modest increases, typically in the 30 to 40 percent range above baseline, but the direction and mechanism are the same.

Patients in months two and three often report that the body feels different before it looks different. Workout performance improves. Fat around the midsection begins to shift. These changes are real, even when they remain subtle.

Months 4 Through 6: Visible Lean Mass and Fat Loss

This is the window where the work becomes visible. Patients who have been consistent with dosing, sleep, and training generally report measurable changes in lean mass and meaningful reductions in body fat by months four through six.

A 16-week single-blind randomized placebo-controlled trial enrolled 19 participants aged 55 to 71 who self-injected sermorelin at 10 mcg/kg nightly. Results showed significant increases in nocturnal GH levels, significant increases in lean body mass in men, and elevated IGF-1 and IGFBP-3 within two weeks of beginning treatment.

The patients who see the most meaningful results are those who started with low baseline IGF-1, maintain their injection schedule reliably, and are training with resistance exercise three or more times per week. Sermorelin is not a substitute for training stimulus. It is a recovery and signaling amplifier for a training program that is already in place. That patient in his early fifties is now training with IGF-1 at 183 ng/mL and reporting recovery that feels, in his words, like being in his early forties again.

How Sermorelin Intersects With Testosterone

For male patients dealing with both low IGF-1 and suboptimal testosterone, the relationship between the two axes is worth understanding. Sleep deprivation and elevated cortisol suppress both GH and testosterone production through related mechanisms. Restoring slow-wave sleep architecture through GHRH signaling creates hormonal conditions in which nocturnal testosterone production can also improve. For a detailed clinical explanation of this relationship, see The Relationship Between Sermorelin, Growth Hormone, and Testosterone Explained.

Precision Telemed’s Sermorelin Program

At Precision Telemed, the sermorelin program is $149.99 for the first month, then $179.99 per month, fulfilled through 503A compounding pharmacies and managed through async telehealth. The program is available in all 50 states.

FAQ

Q: What is the appropriate sermorelin dosage for muscle growth? The standard clinical range is 200 to 500 micrograms subcutaneously at bedtime. Most patients begin at 200 to 300 mcg and titrate based on IGF-1 response at six to eight weeks. Dosage adjustment without lab monitoring is not recommended.

Q: When is the best time to inject sermorelin? Bedtime, consistently. Sermorelin amplifies the natural nocturnal growth hormone pulse that occurs during slow-wave sleep. Administration in the morning or afternoon misses the biological window during which somatostatin tone falls and GHRH signaling is dominant.

Q: How long does sermorelin take to affect body composition? Most patients notice sleep and recovery improvements within the first two to four weeks. Measurable changes in body composition are generally apparent by months three to six.

Q: Is sermorelin preferable to synthetic HGH for body composition? For most patients seeking sustainable, long-term body composition improvement, sermorelin is the preferred approach. It works through the endogenous pituitary axis, maintains physiological feedback including somatostatin counter-regulation, and does not suppress natural GH production over time.

Q: Can women use sermorelin for body composition? Yes. The clinical trials showing sleep and IGF-1 improvements enrolled both men and women. Women in our practice report consistent improvements in recovery, sleep, energy, and body composition over a six-month course.

Q: What labs should be monitored during sermorelin therapy? IGF-1, IGFBP-3, fasting glucose, and a basic metabolic panel at baseline and at six to eight weeks. IGF-1 is the primary marker for assessing growth hormone axis response.

Q: Does sermorelin interact with other medications? Sermorelin has a favorable safety profile and is well tolerated in most patients. However, patients on thyroid medication, insulin, or glucocorticoids should discuss these with their provider, as growth hormone signaling can affect glucose metabolism and thyroid hormone conversion.

References

1. Steiger A et al. Nocturnal sleep EEG and secretion of GH and cortisol after administration of GHRH. Neuroendocrinology. 1992;56(4):566-573. PubMed
2. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PubMed

To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.

Disclaimer: Compounded tirzepatide and semaglutide are prepared by a licensed 503A compounding pharmacy and have not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

Tirzepatide versus semaglutide is the question that comes into our program almost every day. Someone is starting intake, or three months in and plateauing, or they just read something about Mounjaro. Our clinical team has worked through this comparison thousands of times, and my pharmaceutical background lets me explain the difference from the commercial and operational side.

Here is how I think about it, and what we consistently see across our patient population.

The Mechanism Difference, From a Pharmacological Standpoint

Semaglutide is a GLP-1 receptor agonist. It binds to glucagon-like peptide 1 receptors in the hypothalamus and brainstem, driving satiety and reducing caloric intake, and in the gut, where it slows gastric emptying.

Tirzepatide activates a second receptor pathway semaglutide does not touch: the GIP receptor, which stands for glucose-dependent insulinotropic polypeptide. In pancreatic beta cells, GIP receptor activation enhances glucose-stimulated insulin secretion. In adipose tissue, GIP receptors influence lipid metabolism and fat storage dynamics. The combination of GLP-1 and GIP receptor agonism produces a different biological profile, not simply a stronger version of the same signal.

For a complete mechanistic breakdown, see How Semaglutide Works at a Cellular Level. For muscle preservation considerations relevant to both, see The Protein and Resistance Training Protocol for GLP-1 Patients.

What We Actually See Across Our Patient Population

I’ll be direct about what our clinical team observes: patients on tirzepatide tend to reach their goals more readily than patients on semaglutide, and the difference is noticeable enough that our providers talk about it constantly. That being said, the question of tirzepatide vs semaglutide for weight loss is more nuanced than a simple answer.

The clearest pattern is the plateau transition. Patients who have stalled on semaglutide at a well-tolerated dose frequently restart progress after their provider transitions them to tirzepatide. That is one of the most common adjustments our clinical team manages. Patients with substantially more total weight to lose tend to see a more pronounced difference on tirzepatide. And patients with type 2 diabetes or significant insulin resistance are the population where our providers find the dual mechanism most clinically relevant.

None of that makes semaglutide a weak option. Plenty of patients in our program do very well on it, reach meaningful weight loss, and stay comfortable there. What it means is that when a provider is choosing between the two, the individual clinical picture drives the decision.

How Our Clinical Team Approaches the Choice

Our providers make the actual prescribing decisions. What I observe operationally is that cost and consistency matter as much as raw potency. The price difference between the two is real month over month, and a therapy someone can afford to stay on consistently outperforms a more potent option they stop taking. For a patient doing well on semaglutide at a price they can sustain, there is often no reason to change. For a patient who has plateaued or has more aggressive goals, the conversation shifts. Our providers account for all of that individually. Patients who want to explore the tirzepatide option can review our compounded tirzepatide online program details directly.

A Note on the Current Regulatory Environment

The regulatory landscape for compounded GLP-1 medications has changed materially since 2024. The shortage-based pathway that permitted broad “essentially a copy” compounding of both molecules has ended — tirzepatide’s shortage was declared resolved in late 2024, semaglutide’s in February 2025. The operative framework now is 503A patient-specific compounding, which requires documented clinical justification for each individual prescription. Both compounded tirzepatide and compounded semaglutide are prepared under this framework and have not been reviewed or approved by the FDA as finished drug products. Because they are not FDA-reviewed, their potency and purity are not assured in the way an approved product’s are.

FAQ

Q: Is tirzepatide better than semaglutide for weight loss? In our program, patients on tirzepatide tend to reach their goals more readily, particularly those who plateaued on semaglutide or have more weight to lose. Individual response varies, and our clinical team evaluates each patient’s situation individually. Neither compounded tirzepatide nor compounded semaglutide has been reviewed by the FDA, and outcomes cannot be assumed to match those of the approved products.

Q: Can someone switch from semaglutide to tirzepatide if they stop losing weight? Transitioning between the two is something our clinical team handles regularly. Anyone on our program considering a change should raise it with their provider.

Q: Is tirzepatide more expensive? Yes. Tirzepatide costs more at every step of the supply chain. For patients managing tight budgets, semaglutide remains a meaningful and effective option, and many patients in our program do very well on it.

Q: What happens to weight if someone stops GLP-1 therapy? Appetite regulation tends to return toward baseline after stopping, and many patients find weight returns without a maintenance plan. Our clinical team discusses this before anyone starts so the commitment is understood upfront.

If you want to talk through whether this is right for you, our providers are available online. Start at www.precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.

About the Author: JP Rius is the founder of Precision Telemed with a background in pharmaceutical commercial sales, operations, and trade. Over the past two years, his clinical team has served more than 5,000 patients across weight loss, hormone therapy, peptide therapy, and longevity programs. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

The question I hear most often from patients considering a GLP-1 medication is not “will it work?” Most of them have already read enough to believe it will work. The question I hear most is “will I lose muscle?” It is a real concern, and the answer is nuanced in a way that a quick internet search does not capture well. GLP-1 muscle loss is real, but the degree to which it happens depends enormously on what a patient does around the medication, specifically how much protein they eat and whether they are doing resistance training.

What Lean Mass Loss on GLP-1 Therapy Actually Looks Like

A portion of any significant weight loss comes from lean tissue, not just fat. This is true of weight loss by any method: dietary restriction, bariatric surgery, or GLP-1 therapy. In my clinical experience, GLP-1 medications do not independently accelerate muscle loss beyond what losing weight by any means would produce. A meaningful share of weight lost comes from lean tissue when patients do not engage in structured resistance training, with the majority coming from fat.

The problem is not the drug. The problem is that when appetite suppression reduces food intake significantly, protein often falls along with total calories, and lean tissue pays the price. That is the pattern I see repeatedly in patients who lose weight quickly without a deliberate protein and training plan in place.

The patients who do this program right lose fat. The patients who simply inject without adjusting protein intake lose fat and muscle together. There is a meaningful clinical difference in body composition outcomes between those two groups, and the separating variable is not the medication. It is what happens around it.

For patients considering adding sermorelin to their GLP-1 protocol to further support lean mass through the GH/IGF-1 axis, see The Combination We Prescribe When Patients Want to Lose Weight Without Losing Muscle.

The Leucine Threshold and Why Protein Distribution Matters

Understanding why protein distribution across meals matters requires a brief explanation of how muscle protein synthesis actually works at the cellular level. Muscle protein synthesis is regulated in large part through the mTOR pathway, a cellular signaling system that acts as a nutrient sensor and growth regulator. Among the amino acids that activate mTOR, leucine is the most potent trigger. Research has established a leucine threshold: approximately 2.5 to 3 grams of leucine per meal is required to maximally stimulate muscle protein synthesis via mTOR. Below that threshold, the anabolic response is blunted.

The clinical target I set for patients on GLP-1 therapy includes not just a total daily protein number but a per-meal distribution framework: 1.2 to 1.6 grams of protein per kilogram of body weight per day, distributed across at least three meals, with each meal containing a minimum of 30 to 40 grams of high-quality protein.

What I consistently see in practice is that many patients cannot reliably hit these targets once they are well into therapy, because appetite is substantially blunted. One large protein meal at dinner does not produce the same anabolic effect as three meals each crossing the leucine threshold throughout the day. The mTOR signal fires and fades. It needs to be re-triggered at each meal to sustain the rate of muscle protein synthesis that counteracts the catabolic forces of a caloric deficit.

Resistance Training: The Mechanical Signal That Walking Cannot Replace

The second pillar of the protocol is resistance training, and this is where I encounter the most pushback from patients. Patients who are losing weight are often tired, often dealing with nausea at some point in titration, and often inclined to believe that walking or light cardio is sufficient. The biology says otherwise.

Resistance training preserves muscle through a specific biological mechanism: mechanical tension applied to a muscle triggers the activation of satellite cells, the resident stem cells of skeletal muscle tissue. Satellite cells proliferate and fuse with existing muscle fibers, contributing to myofibrillar protein synthesis and structural repair. This mechanical tension signal is distinct from metabolic or hormonal stimuli. It requires that the muscle be loaded near its capacity to generate the cellular response that signals the body to maintain and rebuild fiber density.

Walking does not provide this stimulus at a meaningful level for most patients. Aerobic exercise has well-documented cardiovascular and metabolic benefits, and I want all patients incorporating regular low-intensity movement. But aerobic exercise and resistance training do different things to skeletal muscle biology. During a caloric deficit, when the body’s default tendency is to catabolize protein from muscle to meet energy needs, resistance training sends a countervailing signal: this tissue is being used, do not sacrifice it. Without that signal, the proportion of lean mass lost during weight reduction is higher than it needs to be.

The protocol I recommend is a minimum of two to three resistance training sessions per week, each focusing on compound movements that recruit large muscle groups: squats, deadlifts, presses, rows, and lunges. Patients who do not have gym access or equipment can achieve adequate mechanical stimulus with bodyweight exercises performed to near muscular failure.

Understanding Hair Loss: The Same Upstream Cause

Patients often come to me alarmed about hair shedding during GLP-1 therapy. The clinical term for this phenomenon is telogen effluvium, and understanding the mechanism explains why it shares an upstream cause with lean mass loss.

The hair follicle cycles through growth phases: anagen is the active growth phase, and telogen is the resting phase from which hair sheds. Under normal conditions, approximately 10 to 15 percent of follicles are in the telogen phase at any time. When the body experiences significant physiological stress, including rapid caloric restriction or major nutritional deficits, a larger-than-normal fraction of follicles shift from anagen into telogen simultaneously. The timing of this shift typically lags the stressor by two to three months, which is why patients often notice hair shedding well after the period of most rapid weight loss began.

Patients who maintain adequate protein intake and avoid severe caloric restriction beyond what the medication naturally produces tend to experience less pronounced hair shedding and faster recovery. Both problems have the same upstream solution: protect protein intake and do not compound the medication’s caloric suppression with additional aggressive dieting.

The Full Protocol in Practice

The protocol I give patients starting a GLP-1 has three components. First, a protein target: 1.2 to 1.6 grams per kilogram of body weight per day, distributed across at least three meals, each crossing the leucine threshold with 30 to 40 grams of protein. Second, resistance training: two to three sessions per week, full body, compound movements performed with enough load to generate real mechanical tension. Third, restraint around additional caloric restriction: let the drug do what it does. Stacking an aggressive low-calorie diet on top of a medication that is already reducing intake significantly produces a deficit larger than needed, a protein shortfall more severe, and a lean mass cost higher than necessary.

Patients who follow this framework lose fat and maintain a substantially higher proportion of lean mass than patients who treat the medication as the only variable in the equation.

FAQ

Q: How much muscle loss is normal on a GLP-1 medication? A portion of the weight lost on GLP-1 therapy comes from lean tissue, with the majority coming from fat. This is comparable to what happens with weight loss through dietary restriction alone. The absolute amount of muscle lost depends significantly on protein intake and resistance training during the weight loss period.

Q: Is resistance training necessary, or is cardio sufficient? Cardiovascular exercise has meaningful health benefits, but it does not provide the mechanical stimulus that signals the body to preserve skeletal muscle during a caloric deficit. Resistance training two to three times per week is the clinically supported approach for muscle preservation. Both are beneficial; resistance training is the component that is non-substitutable for this specific goal.

Q: Why do patients experience hair shedding on GLP-1 medications? Hair shedding during GLP-1 therapy is most often telogen effluvium, a temporary shedding caused by the physiological stress of rapid caloric restriction and nutritional changes. It typically appears two to three months after the period of most rapid restriction and is not caused directly by the medication. Maintaining adequate protein intake reduces its severity and duration.

Q: What if appetite suppression makes hitting protein targets difficult? Protein shakes and protein-fortified foods are clinically appropriate tools for patients on GLP-1 therapy who struggle to reach targets through whole food alone. Prioritizing protein at every meal before moving to other macronutrients, and using a high-quality protein supplement for any meal where targets are difficult to meet, are practical strategies used regularly in our practice.

Q: Can muscle lost during the weight loss phase be recovered? Lean mass lost during the weight loss phase can be regained after reaching a stable weight, particularly with continued resistance training and adequate protein intake. Many patients experience meaningful improvements in body composition during a maintenance phase after active weight loss.

Q: How does Precision Telemed’s program support body composition? Precision Telemed providers offer ongoing async follow-up that includes guidance on nutrition and lifestyle practices during GLP-1 therapy. The goal of the program is not just weight reduction but overall metabolic and body composition improvement.

References

1. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. doi:10.1111/dom.15728
2. Ida S, Kaneko R, Imataka K, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2024. PubMed: 39719170

To speak with one of our licensed providers about whether this is right for you, visit www.precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.

Disclaimer: Compounded NAD+ is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

A patient came to our program after spending the better part of a year doing IV NAD+ infusions at a wellness clinic. She was paying $400 a session, going once a month when she could afford it, then nothing for two or three months when she couldn’t. She shared with our team that the sessions helped — noticeably. She had started to resent a therapy that was working because she couldn’t afford to keep it going.

When our program introduced subcutaneous NAD+ injections at $139.99 for the first month, then $149 a month, she was skeptical — she had been told IV was the only legitimate delivery route. Three months later she reported the same mental clarity and energy consistency she had gotten from the IV sessions, maintained daily rather than spiking and crashing around appointments she could only afford sporadically. That outcome shaped everything about how we built this program.

What NAD+ Is — From a Biochemistry Standpoint

NAD+, or nicotinamide adenine dinucleotide, is a coenzyme present in every cell in the body. I want to explain the underlying science here as someone with a pharmaceutical background, not as clinical guidance.

NAD+ functions as an electron carrier in the mitochondrial electron transport chain — foundational to how cells convert nutrients into ATP. But it is also a consumed substrate for a class of enzymes that govern DNA repair, gene expression, and cellular stress response. Sirtuins (SIRT1 through SIRT7) require NAD+ as a cofactor for every catalytic cycle. SIRT1 regulates gene expression, inflammation, and stress resistance. SIRT3 governs mitochondrial biogenesis and antioxidant defenses within the organelle. PARPs consume NAD+ for DNA repair. CD38, a glycohydrolase involved in immune signaling, is another major consumer.

As we age, NAD+ levels fall. CD38 expression increases with aging and chronic inflammation, cleaving NAD+ continuously. PARPs run continuously in tissues under chronic oxidative stress. NAMPT — the rate-limiting enzyme in the salvage pathway that recycles nicotinamide back to NAD+ — declines in activity. The consumption side accelerates while the synthesis side weakens.

The human clinical evidence is real. Trammell and colleagues documented a 2.7-fold increase in blood NAD+ following a single 1,000 mg dose of NR in healthy human subjects (Trammell et al., Nat Commun 2016, PMID 27721479). Yoshino and colleagues found NMN supplementation produced a 38 percent increase in intramuscular NAD+ and a 25 percent improvement in muscle insulin sensitivity in prediabetic women (Yoshino et al., Science 2021, PMID 34108263). I want to be transparent: a significant portion of mechanistic data comes from animal studies, and large-scale RCTs in humans are still ongoing. The mechanism is well understood; the long-term clinical evidence in humans continues to develop.

For a detailed comparison of subcutaneous versus IV delivery and why consistency matters more than peak concentration, see Why I Recommend Subcutaneous NAD+ Over IV Therapy.

Why the Delivery Model Matters — An Operational Observation

The IV model priced NAD+ therapy out of reach for most people who would benefit from sustained use. Four hundred to six hundred dollars per session, four to ten sessions for a loading protocol, at a clinic that requires hours out of the day. Most patients can’t sustain that, and the benefit tracks consistency — not the magnitude of any single dose.

Subcutaneous NAD+ at home produces lower peak concentration than IV, but more sustained availability across days. For the sirtuin-dependent pathways that require ongoing NAD+ to function, consistent replenishment is more valuable than periodic flooding. What I observed operationally across our patient population — not as a clinical conclusion, but as a pattern — is that patients on consistent subcutaneous protocols described outcomes that matched or exceeded what they’d gotten from sporadic IV sessions they could only afford a few times a year.

What Patients in Our Program Have Reported

The most consistent report from our NAD+ patient population is mental clarity — not a stimulant effect, but a more durable cognitive sharpness that feels less effortful. Sustained energy without relying on caffeine or stimulants is the second theme. Faster physical recovery from training is the third. These are patient-reported observations from our program, not clinical trial results. Individual experiences vary, and our clinical team evaluates each patient’s situation individually.

Who This Is and Is Not For

Our clinical team adds NAD+ to protocols for patients dealing with cognitive fatigue, active patients seeking improved recovery, and patients who have responded well to IV NAD+ but cannot sustain that cost model. It is not positioned as a treatment for disease. Anyone expecting a cure-all will be disappointed — our providers say so directly before moving forward.

For a clinical comparison of IV versus injection delivery, see NAD+ IV Therapy vs Injections: What the Difference Actually Means.

FAQ

What are the reported benefits of NAD+ injections?

Patients in our program most commonly report improved mental clarity, more sustained energy, and faster recovery from physical activity. These are consistent with the known role of NAD+ in mitochondrial energy production and sirtuin activation. Compounded NAD+ has not been reviewed by the FDA. Individual results vary.

How does subcutaneous NAD+ compare to IV NAD+?

IV produces a higher acute peak; subcutaneous produces slower absorption and more consistent availability across days. For ongoing sirtuin activity — which requires NAD+ as a stoichiometric substrate in every catalytic cycle — consistency of replenishment matters more than the magnitude of a single dose.

How much do NAD+ injections cost?

At Precision Telemed, subcutaneous NAD+ injections are $139.99 your first month, then $149 a month. IV NAD+ at wellness clinics typically costs $400–600 per session.

Is the research on NAD+ established?

The mechanism of action is well understood, and human clinical data is growing. Larger long-term RCTs are still ongoing. I am transparent with patients that this is not a therapy with 30 years of phase III trial evidence — and our clinical team has that conversation before anyone starts.

References

1. Trammell SA et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nat Commun. 2016;7:12948. PubMed
2. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed

If you want to talk through whether this is right for you, our providers are available online. Start at precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.

About the Author: JP Rius is the founder of Precision Telemed with a background in pharmaceutical commercial sales, operations, and trade. Over the past two years, his clinical team has served more than 5,000 patients across weight loss, hormone therapy, peptide therapy, and longevity programs. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.

Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.

A patient came in last year who had spent over $3,000 in a single quarter at an IV therapy clinic. The sessions were helping, she said. She felt sharper after each infusion, her energy held better for a week or so. Then her schedule changed and the costs caught up with her, and she stopped entirely. Six weeks later she felt exactly the way she had before she started.

That story reveals something important about NAD IV therapy and the biology of NAD+ restoration: the benefit tracks the consistency of replenishment, not the magnitude of any single dose. Understanding why requires a look at what NAD+ actually does at the cellular level and how its decline with age is driven by mechanisms that do not stop between infusion appointments.

What NAD+ Does and Why Restoration Matters

Nicotinamide adenine dinucleotide is a coenzyme found in every cell of the body. Its most fundamental role is as an electron carrier in metabolic redox reactions, shuttling reducing equivalents into the mitochondrial electron transport chain to drive ATP production. Without sufficient NAD+ to complete this cycling, mitochondrial energy output falls and cells become metabolically constrained.

But NAD+ is also a consumed substrate, not just a cycling carrier, in three critical regulatory pathways. Sirtuins, a family of seven deacetylase enzymes designated SIRT1 through SIRT7, require NAD+ for every catalytic cycle. SIRT1 deacetylates histones and transcription factors to regulate gene expression for inflammation, metabolic adaptation, and stress resistance. SIRT3 governs mitochondrial protein acetylation and protects against oxidative damage. PARPs, or poly-ADP-ribose polymerases, also consume NAD+ as a substrate for DNA repair. CD38, an enzyme with NAD+ glycohydrolase activity involved in immune signaling and calcium mobilization, is another major consumer. These are not minor diversions. They compete for the same NAD+ pool that the mitochondria need to sustain energy output.

The research supporting NAD+ restoration is mechanistically well understood. A landmark 2016 clinical trial led by Charles Brenner and Samuel Trammell, published in Nature Communications, was the first controlled human trial of nicotinamide riboside, an NAD+ precursor. The trial showed dose-dependent increases in blood NAD+ metabolites in healthy human subjects, with blood NAD+ rising as much as 2.7-fold after a single dose. No serious adverse events were observed across 36 days of observation. (PubMed)

Why NAD+ Declines With Age

NAD+ decline is driven by specific, identifiable mechanisms that accelerate over time. CD38 expression increases substantially with age and with chronic low-grade inflammation. As CD38 upregulates, it hydrolyzes NAD+ at an increasing rate, outpacing the body’s capacity to resynthesize it. This is compounded by PARP hyperactivation: decades of accumulated DNA damage mean more strand breaks and more PARP recruitment, each episode drawing down the NAD+ pool. At the same time, NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway that recycles nicotinamide back into NAD+, declines in activity with age. The synthesis side weakens while the consumption side accelerates.

This mechanism matters for treatment decisions. If the problem were simply inadequate dietary intake, a single large dose once a month might suffice. But the problem is continuous enzymatic consumption that does not pause between appointments. The replenishment strategy needs to match the consumption pattern.

NAD IV Therapy: The Clinical Case and the Real Limitations

Intravenous NAD+ infusion delivers the coenzyme directly into circulation, achieving 100 percent bioavailability. A standard IV session uses 250 to 1,000 mg of NAD+ dissolved in saline, infused over two to four hours. The acute elevation in plasma NAD+ is rapid and substantial. For patients with severe depletion or who are going through addiction recovery protocols, that acute loading can be clinically appropriate and the high peak concentration may have specific therapeutic value.

But for the large majority of patients pursuing longevity, cognitive performance, metabolic health, and energy, the IV model creates practical barriers that undermine the very consistency the biology requires. Sessions cost $400 to $600 each. They require patients to take two to four hours out of their day, travel to a clinic, and sit attached to an IV line. Loading protocols often call for four to ten sessions over two to four weeks, a financial and logistical burden most patients cannot sustain. When patients stop, the benefit stops. NAD+ does not accumulate indefinitely. The CD38 enzymes keep working. The PARPs keep responding to DNA damage. The NAD+ that was transiently elevated is metabolized and cleared within hours to days, and the problem reasserts itself.

Why Subcutaneous Injection Achieves Comparable Systemic Results

Subcutaneous NAD+ injection delivers the compound into the tissue just below the skin, where it is absorbed steadily into systemic circulation. The bioavailability is lower than IV, approximately 70 to 80 percent, but the pharmacokinetics are actually favorable for the sustained cellular replenishment that sirtuin activation requires. Rather than a single large spike that peaks and then clears, subcutaneous injection delivers a more gradual, sustained elevation of plasma NAD+.

What the research supports is that for long-term outcomes, frequency of replenishment matters more than the route of a single large dose. Consistent, repeated elevation of NAD+ supports ongoing sirtuin activity, sustained mitochondrial function, and continuous DNA repair processes. The sirtuin enzymes require NAD+ as a stoichiometric substrate: every deacetylation reaction consumes one molecule of NAD+. Maintaining the baseline concentration that keeps SIRT1 and SIRT3 active requires steady replenishment, not periodic flooding.

Yoshino and colleagues, writing in Science in 2021, conducted a randomized, double-blind, placebo-controlled trial showing that NAD+ precursor supplementation increased intramuscular NAD+ levels by 38 percent and improved insulin sensitivity in skeletal muscle by 25 percent in prediabetic women, with SIRT1 activation confirmed by RNA sequencing. (PubMed) The delivery route in that trial was oral, not IV — reinforcing that tissue-level NAD+ elevation sufficient to activate sirtuins and improve metabolic function does not require intravenous delivery.

The Cost Reality and What Sustainability Actually Means

At Precision Telemed, the NAD+ program is $149.99 per month. A single IV session at a typical IV therapy clinic costs more than that. Two IV sessions per month, a conservative maintenance schedule by those clinics’ own protocols, costs $800 to $1,200 monthly.

Sustainable, in this context, is not a marketing word. It is a biological requirement. A therapy that raises NAD+ for three weeks and then disappears for a month does not confer lasting sirtuin activation. It does not produce durable mitochondrial improvement. The subcutaneous model at home, administered twice weekly during loading and then weekly for maintenance, is designed to match the biology. It keeps the NAD+ pool elevated continuously rather than cycling it sharply up and down.

Patients self-inject using a small insulin-gauge needle into the abdomen or outer thigh. The process takes under two minutes. There is no clinic visit, no IV line, and no $500 session fee.

How I Structure NAD+ Protocols at Precision Telemed

For most patients, I start with twice-weekly subcutaneous injections for the first four to six weeks as a loading phase, then taper to once weekly for maintenance. Patients report improvements in mental clarity, energy stability, sleep quality, and exercise recovery within the first two to four weeks of consistent use. The cognitive improvements, which are often what patients notice first — are consistent with SIRT1-mediated neurological effects and the mitochondrial energy requirements of neural tissue.

For patients managing metabolic conditions, age-related fatigue, or neurological symptoms, I may maintain the twice-weekly schedule longer before stepping down. The async model at Precision Telemed allows follow-up on lab values and symptom tracking without requiring in-person visits.

FAQ

Q: Is subcutaneous NAD+ as effective as IV therapy? For most patients pursuing sustained longevity and metabolic benefits, yes. IV therapy achieves a higher acute plasma NAD+ peak, but subcutaneous injection at regular intervals maintains the consistent baseline elevation that drives ongoing sirtuin activation and mitochondrial support. For sirtuin enzymes that require NAD+ as a stoichiometric substrate in every catalytic cycle, frequency of replenishment matters more than the magnitude of any single dose.

Q: How often should subcutaneous NAD+ be administered? Most protocols use twice weekly for the first four to six weeks as a loading phase, then once weekly for ongoing maintenance. The treating provider adjusts this based on symptoms and treatment goals.

Q: What does NAD+ actually do in the body? NAD+ functions as an electron carrier in mitochondrial redox reactions that produce ATP, and as a consumed substrate for sirtuin enzymes (SIRT1-7), PARP DNA repair enzymes, and CD38. Its decline with age reduces cellular energy output, impairs DNA repair, and suppresses sirtuin-mediated gene regulation.

Q: Why does NAD+ decline with age? CD38 expression increases with age and chronic inflammation, hydrolyzing NAD+ at an accelerating rate. PARP hyperactivation from accumulated DNA damage adds to consumption. Meanwhile, NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, declines in activity. The result is a progressive imbalance between consumption and synthesis.

Q: Is self-injection at home safe? Yes, with proper instruction. Subcutaneous injection with an insulin-gauge needle into the abdomen or outer thigh is a well-established and low-risk technique. Precision Telemed patients receive complete injection education as part of their onboarding.

Q: How is Precision Telemed’s NAD+ program different from an IV clinic? Cost and consistency are the primary differences. At $149.99 per month, the program costs a fraction of a single IV session at most clinics. It is delivered to the patient’s door, administered at home in under two minutes, and managed asynchronously by a licensed provider. The weekly or twice-weekly schedule is designed to maintain NAD+ at biologically active levels continuously rather than episodically.

Q: Can NAD+ help with brain fog and cognitive performance? The research on SIRT1-mediated neurological regulation and the mitochondrial energy requirements of neural tissue is compelling, and many patients in our practice report meaningful improvements in clarity and sustained mental energy within the first few weeks of consistent use. This is positioned as a supportive intervention that addresses a documented biological mechanism — not a treatment for any diagnosed neurological condition.

References

1. Trammell SA et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nat Commun. 2016;7:12948. PubMed
2. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed

To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.

This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.

Disclaimer: Compounded testosterone cypionate is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

A patient reached out to our program last year, about a week after his first consultation at a men’s clinic near him. He had gone in curious, left with a treatment plan, and then opened the invoice. He was looking at $450 a month, not including labs every three months. He made $62,000 a year. He said: “I can’t do this.” He was ready to just accept feeling the way he felt.

That call is why I address pricing in the first conversation, not the last. And it’s why I want to explain what TRT actually costs; what drives that cost, and where our $199 flat rate comes from — from someone with a pharmaceutical commercial background who understands what’s really going on in this market.

What’s In the Medication and Why the Price Isn’t What It Appears

Testosterone cypionate is the most widely prescribed form of injectable TRT. From a pharmaceutical manufacturing standpoint, it is not a complex or expensive compound to produce. Testosterone cypionate is esterified testosterone, a cypionate ester group attached at the C17 position, which gives it a half-life of approximately eight days and makes weekly or twice-weekly dosing practical. A 503A compounding pharmacy can produce a ten-week supply for a fraction of what traditional clinics charge.

The markup at most men’s health clinics has almost nothing to do with the cost of the drug. What patients are paying for is the building, the front desk, the PA, and a business model built around in-person volume. That’s the commercial reality, and it’s something my pharmaceutical trade background makes easy to see clearly.

The Pharmacology Behind Why Monitoring Is Part of the Cost

I want to explain what our clinical program includes and why, not as medical guidance, but as someone who understands the underlying pharmacology and built a program around it.

Testosterone operates within the hypothalamic-pituitary-testicular axis. When exogenous testosterone is introduced, the body’s feedback loop suppresses endogenous GnRH and LH, which reduces the testes’ own output. That is pharmacologically expected and something our clinical team discusses with every patient before they start. The Bhasin 2018 Endocrine Society guidelines establish diagnostic criteria, two separate morning total testosterone measurements below 300 ng/dL on different days. (Bhasin et al., J Clin Endocrinol Metab 2018, PMID 29562364).

Testosterone also has erythropoietic effects — it stimulates EPO production, which drives increased red blood cell production and raises hematocrit over time. That has cardiovascular implications at elevated levels. Our clinical team monitors hematocrit, total and free testosterone, and estradiol on a standard schedule. The lab work is not overhead I’m passing through to generate revenue. It’s the clinical obligation that comes with the therapy, and it’s why the program cost needs to include physician oversight, not just medication.

Testosterone also aromatizes to estradiol via the CYP19A1 enzyme. Our program includes anastrozole, an aromatase inhibitor, as a standard component rather than an add-on, because managing that ratio is part of doing this properly.

For a clinical explanation of side effects and what to expect, see Side Effects of Testosterone Injections: What to Expect.

What the $199 Flat Rate Includes

Our foundational TRT program is $199 a month. That covers testosterone cypionate compounded at our 503A pharmacy and shipped, anastrozole, and physician oversight — a licensed provider reviews each patient’s case, adjusts the protocol, and remains available through our telehealth platform. Baseline lab review is included when patients come in with existing labs.

I built the program this way because medication and medical oversight should be a single unit, not separated into individual line items to inflate the total. The clinics charging $500 a month are not necessarily doing better medicine. The services charging $50 with no real oversight are not doing medicine at all. We sit between those two points — pricing that is honest, oversight that is real.

What the Program Does Not Include

Our program is fully remote with no office visits or in-person physical exams. Ongoing labs are not bundled into the $199. We route patients to direct-pay lab companies where the relevant panel typically runs $50 to $80 out of pocket. Additional therapies carry separate pricing and are presented transparently before anything is added to a protocol.

Some patients exploring TRT also benefit from sermorelin to support the growth hormone axis alongside testosterone. For how those two systems interact, see Does Sermorelin Increase Testosterone?.

Why Insurance Almost Never Covers This

TRT prescribed for low testosterone is almost universally excluded from standard insurance coverage, even with confirmed labs. Insurers frequently reject claims on grounds that the condition is manageable without treatment, or because the medication is compounded rather than a branded pharmaceutical. Planning for out-of-pocket cost is the realistic approach.

$199 with real physician involvement is not a discounted version of TRT. It is what TRT should cost when the overhead is honest and the science is respected.

FAQ

How much does TRT cost per month without insurance? Most men’s health clinics charge $400–600 a month for a full TRT program including medication and physician oversight. At Precision Telemed, our program is $199 a month and includes compounded testosterone cypionate, anastrozole, and provider management. Compounded testosterone cypionate has not been reviewed by the FDA and is not the same as commercially available testosterone products.

What is included in Precision Telemed’s TRT program? The $199 monthly fee covers compounded testosterone cypionate, anastrozole, and physician oversight through our telehealth platform. Labs are not bundled but we guide patients to affordable direct-pay options.

Why does compounded testosterone cost less than a traditional clinic? The medication itself is not expensive to produce. What inflates pricing at most clinics is facility overhead, staffing, and an in-person business model — not the drug.

Do I need labs before starting? Our clinical providers require it. They follow Bhasin 2018 Endocrine Society diagnostic guidelines. A lab order is provided for patients who don’t have current results, and we route patients to direct-pay labs to keep that cost manageable.

Is online TRT as safe as visiting a clinic? When managed by a licensed physician monitoring labs and adjusting the protocol, the oversight is what matters — not the physical location of the provider. Our clinical team handles that through the platform.

References

1. Hackett G et al. Testosterone replacement therapy: practical aspects. Ther Adv Urol. 2015;7(4):198-209. PubMed
2. Bhasin S et al. Testosterone Therapy in Men with Hypogonadism. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed

If you want to talk through whether this is right for you, our providers are available online. Start at precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.